ARTICLE | Clinical News
NantKwest begins Phase I of NK cell therapy for solid tumors
October 27, 2017 9:43 PM UTC
NantKwest Inc. (NASDAQ:NK) began the 2-part Phase I QUILT-3.028 trial of its haNK cell therapy to treat metastatic or locally advanced solid tumors. The first part of the 16-patient trial will evaluate weekly infusions of 2x109 and 4x109 cells followed by a dose-expansion second part. The open-label, U.S. trial's primary endpoints are maximum tolerated dose (MTD), dose-limiting toxicities (DLTs) and safety. Secondary endpoints include objective response rate (ORR), progression-free survival (PFS) and overall survival (OS)...
BCIQ Company Profiles